Report Detail

Request for Sample of this report

Pharma & Healthcare Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Biosimilar Monoclonal Antibodies Market 2018, Forecast to 2023

  • RnM2733518
    • |
  • 07 January, 2019
    • |
  • Global
    • |
  • 133 Pages
    • |
  • GIR (Global Info Research)
    • |
  • Pharma & Healthcare

A monoclonal antibody is a type of protein made in the laboratory that can bind to substances in the body, including cancer cells. A monoclonal antibody is made so that it binds to only one substance to treat different types of cancer. There are several types of monoclonal antibodies that are being used to treat certain types of cancer. Laboratory production of monoclonal antibodies is produced from clones of only one cell which means that every monoclonal antibody produced by the cell is the same due to which they are called as biosimilar monoclonal antibodies. Each monoclonal antibody recognizes one particular protein. They work in different ways depending on the protein they are targeting, hence different monoclonal antibodies are required to be made to target different types of cancer.

Scope of the Report:
This report focuses on the Biosimilar Monoclonal Antibodies in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The worldwide market for Biosimilar Monoclonal Antibodies is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers
Pfizer, Inc.
Novartis AG
Reliance Life Sciences
Allergan plc
Coherus BioSciences, Inc.
Biocon
Dr. Reddy's Laboratories Ltd.
Boehringer Ingelheim GmbH
BioXpress Therapeutics SA
Intas Pharmaceuticals Limited
BIOCAD
Genor BioPharma Co. Ltd
Celltrion, Inc.

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Rituximab
Infliximab
Abciximab
Trastuzumab
Adalimumab
Bevacizumab

Market Segment by Applications, can be divided into
Oncology
Chronic and Autoimmune Diseases
Growth Hormone Deficiency
Infectious Diseases
Others

There are 15 Chapters to deeply display the global Biosimilar Monoclonal Antibodies market.
Chapter 1, to describe Biosimilar Monoclonal Antibodies Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Biosimilar Monoclonal Antibodies, with sales, revenue, and price of Biosimilar Monoclonal Antibodies, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Biosimilar Monoclonal Antibodies, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Biosimilar Monoclonal Antibodies market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Biosimilar Monoclonal Antibodies sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source


Table of Contents

    1 Market Overview

    • 1.1 Biosimilar Monoclonal Antibodies Introduction
    • 1.2 Market Analysis by Type
      • 1.2.1 Rituximab
      • 1.2.2 Infliximab
      • 1.2.3 Abciximab
      • 1.2.4 Trastuzumab
      • 1.2.5 Adalimumab
      • 1.2.6 Bevacizumab
    • 1.3 Market Analysis by Applications
      • 1.3.1 Oncology
      • 1.3.2 Chronic and Autoimmune Diseases
      • 1.3.3 Growth Hormone Deficiency
      • 1.3.4 Infectious Diseases
      • 1.3.5 Others
    • 1.4 Market Analysis by Regions
      • 1.4.1 North America (United States, Canada and Mexico)
        • 1.4.1.1 United States Market States and Outlook (2013-2023)
        • 1.4.1.2 Canada Market States and Outlook (2013-2023)
        • 1.4.1.3 Mexico Market States and Outlook (2013-2023)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy)
        • 1.4.2.1 Germany Market States and Outlook (2013-2023)
        • 1.4.2.2 France Market States and Outlook (2013-2023)
        • 1.4.2.3 UK Market States and Outlook (2013-2023)
        • 1.4.2.4 Russia Market States and Outlook (2013-2023)
        • 1.4.2.5 Italy Market States and Outlook (2013-2023)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
        • 1.4.3.1 China Market States and Outlook (2013-2023)
        • 1.4.3.2 Japan Market States and Outlook (2013-2023)
        • 1.4.3.3 Korea Market States and Outlook (2013-2023)
        • 1.4.3.4 India Market States and Outlook (2013-2023)
        • 1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
      • 1.4.4 South America, Middle East and Africa
        • 1.4.4.1 Brazil Market States and Outlook (2013-2023)
        • 1.4.4.2 Egypt Market States and Outlook (2013-2023)
        • 1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
        • 1.4.4.4 South Africa Market States and Outlook (2013-2023)
        • 1.4.4.5 Nigeria Market States and Outlook (2013-2023)
    • 1.5 Market Dynamics
      • 1.5.1 Market Opportunities
      • 1.5.2 Market Risk
      • 1.5.3 Market Driving Force

    2 Manufacturers Profiles

    • 2.1 Pfizer, Inc.
      • 2.1.1 Business Overview
        • 2.1.1.1 Pfizer, Inc. Description
        • 2.1.1.2 Pfizer, Inc. Headquarter, Main Business and Finance Overview
      • 2.1.2 Pfizer, Inc. Biosimilar Monoclonal Antibodies Product Introduction
        • 2.1.2.1 Biosimilar Monoclonal Antibodies Production Bases, Sales Regions and Major Competitors
        • 2.1.2.2 Biosimilar Monoclonal Antibodies Product Information
      • 2.1.3 Pfizer, Inc. Biosimilar Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.1.3.1 Pfizer, Inc. Biosimilar Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.1.3.2 Global Pfizer, Inc. Biosimilar Monoclonal Antibodies Market Share in 2017
    • 2.2 Novartis AG
      • 2.2.1 Business Overview
        • 2.2.1.1 Novartis AG Description
        • 2.2.1.2 Novartis AG Headquarter, Main Business and Finance Overview
      • 2.2.2 Novartis AG Biosimilar Monoclonal Antibodies Product Introduction
        • 2.2.2.1 Biosimilar Monoclonal Antibodies Production Bases, Sales Regions and Major Competitors
        • 2.2.2.2 Biosimilar Monoclonal Antibodies Product Information
      • 2.2.3 Novartis AG Biosimilar Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.2.3.1 Novartis AG Biosimilar Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.2.3.2 Global Novartis AG Biosimilar Monoclonal Antibodies Market Share in 2017
    • 2.3 Reliance Life Sciences
      • 2.3.1 Business Overview
        • 2.3.1.1 Reliance Life Sciences Description
        • 2.3.1.2 Reliance Life Sciences Headquarter, Main Business and Finance Overview
      • 2.3.2 Reliance Life Sciences Biosimilar Monoclonal Antibodies Product Introduction
        • 2.3.2.1 Biosimilar Monoclonal Antibodies Production Bases, Sales Regions and Major Competitors
        • 2.3.2.2 Biosimilar Monoclonal Antibodies Product Information
      • 2.3.3 Reliance Life Sciences Biosimilar Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.3.3.1 Reliance Life Sciences Biosimilar Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.3.3.2 Global Reliance Life Sciences Biosimilar Monoclonal Antibodies Market Share in 2017
    • 2.4 Allergan plc
      • 2.4.1 Business Overview
        • 2.4.1.1 Allergan plc Description
        • 2.4.1.2 Allergan plc Headquarter, Main Business and Finance Overview
      • 2.4.2 Allergan plc Biosimilar Monoclonal Antibodies Product Introduction
        • 2.4.2.1 Biosimilar Monoclonal Antibodies Production Bases, Sales Regions and Major Competitors
        • 2.4.2.2 Biosimilar Monoclonal Antibodies Product Information
      • 2.4.3 Allergan plc Biosimilar Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.4.3.1 Allergan plc Biosimilar Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.4.3.2 Global Allergan plc Biosimilar Monoclonal Antibodies Market Share in 2017
    • 2.5 Coherus BioSciences, Inc.
      • 2.5.1 Business Overview
        • 2.5.1.1 Coherus BioSciences, Inc. Description
        • 2.5.1.2 Coherus BioSciences, Inc. Headquarter, Main Business and Finance Overview
      • 2.5.2 Coherus BioSciences, Inc. Biosimilar Monoclonal Antibodies Product Introduction
        • 2.5.2.1 Biosimilar Monoclonal Antibodies Production Bases, Sales Regions and Major Competitors
        • 2.5.2.2 Biosimilar Monoclonal Antibodies Product Information
      • 2.5.3 Coherus BioSciences, Inc. Biosimilar Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.5.3.1 Coherus BioSciences, Inc. Biosimilar Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.5.3.2 Global Coherus BioSciences, Inc. Biosimilar Monoclonal Antibodies Market Share in 2017
    • 2.6 Biocon
      • 2.6.1 Business Overview
        • 2.6.1.1 Biocon Description
        • 2.6.1.2 Biocon Headquarter, Main Business and Finance Overview
      • 2.6.2 Biocon Biosimilar Monoclonal Antibodies Product Introduction
        • 2.6.2.1 Biosimilar Monoclonal Antibodies Production Bases, Sales Regions and Major Competitors
        • 2.6.2.2 Biosimilar Monoclonal Antibodies Product Information
      • 2.6.3 Biocon Biosimilar Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.6.3.1 Biocon Biosimilar Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.6.3.2 Global Biocon Biosimilar Monoclonal Antibodies Market Share in 2017
    • 2.7 Dr. Reddy's Laboratories Ltd.
      • 2.7.1 Business Overview
        • 2.7.1.1 Dr. Reddy's Laboratories Ltd. Description
        • 2.7.1.2 Dr. Reddy's Laboratories Ltd. Headquarter, Main Business and Finance Overview
      • 2.7.2 Dr. Reddy's Laboratories Ltd. Biosimilar Monoclonal Antibodies Product Introduction
        • 2.7.2.1 Biosimilar Monoclonal Antibodies Production Bases, Sales Regions and Major Competitors
        • 2.7.2.2 Biosimilar Monoclonal Antibodies Product Information
      • 2.7.3 Dr. Reddy's Laboratories Ltd. Biosimilar Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.7.3.1 Dr. Reddy's Laboratories Ltd. Biosimilar Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.7.3.2 Global Dr. Reddy's Laboratories Ltd. Biosimilar Monoclonal Antibodies Market Share in 2017
    • 2.8 Boehringer Ingelheim GmbH
      • 2.8.1 Business Overview
        • 2.8.1.1 Boehringer Ingelheim GmbH Description
        • 2.8.1.2 Boehringer Ingelheim GmbH Headquarter, Main Business and Finance Overview
      • 2.8.2 Boehringer Ingelheim GmbH Biosimilar Monoclonal Antibodies Product Introduction
        • 2.8.2.1 Biosimilar Monoclonal Antibodies Production Bases, Sales Regions and Major Competitors
        • 2.8.2.2 Biosimilar Monoclonal Antibodies Product Information
      • 2.8.3 Boehringer Ingelheim GmbH Biosimilar Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.8.3.1 Boehringer Ingelheim GmbH Biosimilar Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.8.3.2 Global Boehringer Ingelheim GmbH Biosimilar Monoclonal Antibodies Market Share in 2017
    • 2.9 BioXpress Therapeutics SA
      • 2.9.1 Business Overview
        • 2.9.1.1 BioXpress Therapeutics SA Description
        • 2.9.1.2 BioXpress Therapeutics SA Headquarter, Main Business and Finance Overview
      • 2.9.2 BioXpress Therapeutics SA Biosimilar Monoclonal Antibodies Product Introduction
        • 2.9.2.1 Biosimilar Monoclonal Antibodies Production Bases, Sales Regions and Major Competitors
        • 2.9.2.2 Biosimilar Monoclonal Antibodies Product Information
      • 2.9.3 BioXpress Therapeutics SA Biosimilar Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.9.3.1 BioXpress Therapeutics SA Biosimilar Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.9.3.2 Global BioXpress Therapeutics SA Biosimilar Monoclonal Antibodies Market Share in 2017
    • 2.10 Intas Pharmaceuticals Limited
      • 2.10.1 Business Overview
        • 2.10.1.1 Intas Pharmaceuticals Limited Description
        • 2.10.1.2 Intas Pharmaceuticals Limited Headquarter, Main Business and Finance Overview
      • 2.10.2 Intas Pharmaceuticals Limited Biosimilar Monoclonal Antibodies Product Introduction
        • 2.10.2.1 Biosimilar Monoclonal Antibodies Production Bases, Sales Regions and Major Competitors
        • 2.10.2.2 Biosimilar Monoclonal Antibodies Product Information
      • 2.10.3 Intas Pharmaceuticals Limited Biosimilar Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.10.3.1 Intas Pharmaceuticals Limited Biosimilar Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
        • 2.10.3.2 Global Intas Pharmaceuticals Limited Biosimilar Monoclonal Antibodies Market Share in 2017
    • 2.11 BIOCAD
      • 2.11.1 Business Overview
      • 2.11.2 BIOCAD Biosimilar Monoclonal Antibodies Product Introduction
      • 2.11.3 BIOCAD Biosimilar Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    • 2.12 Genor BioPharma Co. Ltd
      • 2.12.1 Business Overview
      • 2.12.2 Genor BioPharma Co. Ltd Biosimilar Monoclonal Antibodies Product Introduction
      • 2.12.3 Genor BioPharma Co. Ltd Biosimilar Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
    • 2.13 Celltrion, Inc.
      • 2.13.1 Business Overview
      • 2.13.2 Celltrion, Inc. Biosimilar Monoclonal Antibodies Product Introduction
      • 2.13.3 Celltrion, Inc. Biosimilar Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    3 Global Biosimilar Monoclonal Antibodies Market Competition, by Manufacturer

    • 3.1 Global Biosimilar Monoclonal Antibodies Sales and Market Share by Manufacturer (2016-2017)
    • 3.2 Global Biosimilar Monoclonal Antibodies Revenue and Market Share by Manufacturer (2016-2017)
    • 3.3 Global Biosimilar Monoclonal Antibodies Price by Manufacturer (2016-2017)
    • 3.4 Market Concentration Rate
      • 3.4.1 Top 3 Biosimilar Monoclonal Antibodies Manufacturer Market Share in 2017
      • 3.4.2 Top 5 Biosimilar Monoclonal Antibodies Manufacturer Market Share in 2017
    • 3.5 Market Competition Trend

    4 Global Biosimilar Monoclonal Antibodies Market Analysis by Regions

    • 4.1 Global Biosimilar Monoclonal Antibodies Sales, Revenue and Market Share by Regions
      • 4.1.1 Global Biosimilar Monoclonal Antibodies Sales by Regions (2013-2018)
      • 4.1.2 Global Biosimilar Monoclonal Antibodies Revenue by Regions (2013-2018)
    • 4.2 North America Biosimilar Monoclonal Antibodies Sales, Revenue and Growth Rate (2013-2018)
    • 4.3 Europe Biosimilar Monoclonal Antibodies Sales, Revenue and Growth Rate (2013-2018)
    • 4.4 Asia-Pacific Biosimilar Monoclonal Antibodies Sales, Revenue and Growth Rate (2013-2018)
    • 4.5 South America Biosimilar Monoclonal Antibodies Sales, Revenue and Growth Rate (2013-2018)
    • 4.6 Middle East and Africa Biosimilar Monoclonal Antibodies Sales, Revenue and Growth Rate (2013-2018)

    5 North America Biosimilar Monoclonal Antibodies by Countries, Type, Application and Manufacturers

    • 5.1 North America Biosimilar Monoclonal Antibodies Sales, Revenue and Market Share by Countries
      • 5.1.1 North America Biosimilar Monoclonal Antibodies Sales by Countries (2013-2018)
      • 5.1.2 North America Biosimilar Monoclonal Antibodies Revenue by Countries (2013-2018)
      • 5.1.3 United States Biosimilar Monoclonal Antibodies Sales and Growth Rate (2013-2018)
      • 5.1.4 Canada Biosimilar Monoclonal Antibodies Sales and Growth Rate (2013-2018)
      • 5.1.5 Mexico Biosimilar Monoclonal Antibodies Sales and Growth Rate (2013-2018)
    • 5.2 North America Biosimilar Monoclonal Antibodies Sales and Revenue (Value) by Manufacturers (2016-2017)
      • 5.2.1 North America Biosimilar Monoclonal Antibodies Sales by Manufacturers (2016-2017)
      • 5.2.2 North America Biosimilar Monoclonal Antibodies Revenue by Manufacturers (2016-2017)
    • 5.3 North America Biosimilar Monoclonal Antibodies Sales, Revenue and Market Share by Type (2013-2018)
      • 5.3.1 North America Biosimilar Monoclonal Antibodies Sales and Sales Share by Type (2013-2018)
      • 5.3.2 North America Biosimilar Monoclonal Antibodies Revenue and Revenue Share by Type (2013-2018)
    • 5.4 North America Biosimilar Monoclonal Antibodies Sales, Revenue and Market Share by Application (2013-2018)
      • 5.4.1 North America Biosimilar Monoclonal Antibodies Sales and Sales Share by Application (2013-2018)
      • 5.4.2 North America Biosimilar Monoclonal Antibodies Revenue and Revenue Share by Application (2013-2018)

    6 Europe Biosimilar Monoclonal Antibodies by Countries, Type, Application and Manufacturers

    • 6.1 Europe Biosimilar Monoclonal Antibodies Sales, Revenue and Market Share by Countries
      • 6.1.1 Europe Biosimilar Monoclonal Antibodies Sales by Countries (2013-2018)
      • 6.1.2 Europe Biosimilar Monoclonal Antibodies Revenue by Countries (2013-2018)
      • 6.1.3 Germany Biosimilar Monoclonal Antibodies Sales and Growth Rate (2013-2018)
      • 6.1.4 UK Biosimilar Monoclonal Antibodies Sales and Growth Rate (2013-2018)
      • 6.1.5 France Biosimilar Monoclonal Antibodies Sales and Growth Rate (2013-2018)
      • 6.1.6 Russia Biosimilar Monoclonal Antibodies Sales and Growth Rate (2013-2018)
      • 6.1.7 Italy Biosimilar Monoclonal Antibodies Sales and Growth Rate (2013-2018)
    • 6.2 Europe Biosimilar Monoclonal Antibodies Sales and Revenue (Value) by Manufacturers (2016-2017)
      • 6.2.1 Europe Biosimilar Monoclonal Antibodies Sales by Manufacturers (2016-2017)
      • 6.2.2 Europe Biosimilar Monoclonal Antibodies Revenue by Manufacturers (2016-2017)
    • 6.3 Europe Biosimilar Monoclonal Antibodies Sales, Revenue and Market Share by Type (2013-2018)
      • 6.3.1 Europe Biosimilar Monoclonal Antibodies Sales and Sales Share by Type (2013-2018)
      • 6.3.2 Europe Biosimilar Monoclonal Antibodies Revenue and Revenue Share by Type (2013-2018)
    • 6.4 Europe Biosimilar Monoclonal Antibodies Sales, Revenue and Market Share by Application (2013-2018)
      • 6.4.1 Europe Biosimilar Monoclonal Antibodies Sales and Sales Share by Application (2013-2018)
      • 6.4.2 Europe Biosimilar Monoclonal Antibodies Revenue and Revenue Share by Application (2013-2018)

    7 Asia-Pacific Biosimilar Monoclonal Antibodies by Countries, Type, Application and Manufacturers

    • 7.1 Asia-Pacific Biosimilar Monoclonal Antibodies Sales, Revenue and Market Share by Countries
      • 7.1.1 Asia-Pacific Biosimilar Monoclonal Antibodies Sales by Countries (2013-2018)
      • 7.1.2 Asia-Pacific Biosimilar Monoclonal Antibodies Revenue by Countries (2013-2018)
      • 7.1.3 China Biosimilar Monoclonal Antibodies Sales and Growth Rate (2013-2018)
      • 7.1.4 Japan Biosimilar Monoclonal Antibodies Sales and Growth Rate (2013-2018)
      • 7.1.5 Korea Biosimilar Monoclonal Antibodies Sales and Growth Rate (2013-2018)
      • 7.1.6 India Biosimilar Monoclonal Antibodies Sales and Growth Rate (2013-2018)
      • 7.1.7 Southeast Asia Biosimilar Monoclonal Antibodies Sales and Growth Rate (2013-2018)
    • 7.2 Asia-Pacific Biosimilar Monoclonal Antibodies Sales and Revenue (Value) by Manufacturers (2016-2017)
      • 7.2.1 Asia-Pacific Biosimilar Monoclonal Antibodies Sales by Manufacturers (2016-2017)
      • 7.2.2 Asia-Pacific Biosimilar Monoclonal Antibodies Revenue by Manufacturers (2016-2017)
    • 7.3 Asia-Pacific Biosimilar Monoclonal Antibodies Sales, Revenue and Market Share by Type (2013-2018)
      • 7.3.1 Asia-Pacific Biosimilar Monoclonal Antibodies Sales and Sales Share by Type (2013-2018)
      • 7.3.2 Asia-Pacific Biosimilar Monoclonal Antibodies Revenue and Revenue Share by Type (2013-2018)
    • 7.4 Asia-Pacific Biosimilar Monoclonal Antibodies Sales, Revenue and Market Share by Application (2013-2018)
      • 7.4.1 Asia-Pacific Biosimilar Monoclonal Antibodies Sales and Sales Share by Application (2013-2018)
      • 7.4.2 Asia-Pacific Biosimilar Monoclonal Antibodies Revenue and Revenue Share by Application (2013-2018)

    8 South America Biosimilar Monoclonal Antibodies by Countries, Type, Application and Manufacturers

    • 8.1 South America Biosimilar Monoclonal Antibodies Sales, Revenue and Market Share by Countries
      • 8.1.1 South America Biosimilar Monoclonal Antibodies Sales by Countries (2013-2018)
      • 8.1.2 South America Biosimilar Monoclonal Antibodies Revenue by Countries (2013-2018)
      • 8.1.3 Brazil Biosimilar Monoclonal Antibodies Sales and Growth Rate (2013-2018)
      • 8.1.4 Argentina Biosimilar Monoclonal Antibodies Sales and Growth Rate (2013-2018)
      • 8.1.5 Colombia Biosimilar Monoclonal Antibodies Sales and Growth Rate (2013-2018)
    • 8.2 South America Biosimilar Monoclonal Antibodies Sales and Revenue (Value) by Manufacturers (2016-2017)
      • 8.2.1 South America Biosimilar Monoclonal Antibodies Sales by Manufacturers (2016-2017)
      • 8.2.2 South America Biosimilar Monoclonal Antibodies Revenue by Manufacturers (2016-2017)
    • 8.3 South America Biosimilar Monoclonal Antibodies Sales, Revenue and Market Share by Type (2013-2018)
      • 8.3.1 South America Biosimilar Monoclonal Antibodies Sales and Sales Share by Type (2013-2018)
      • 8.3.2 South America Biosimilar Monoclonal Antibodies Revenue and Revenue Share by Type (2013-2018)
    • 8.4 South America Biosimilar Monoclonal Antibodies Sales, Revenue and Market Share by Application (2013-2018)
      • 8.4.1 South America Biosimilar Monoclonal Antibodies Sales and Sales Share by Application (2013-2018)
      • 8.4.2 South America Biosimilar Monoclonal Antibodies Revenue and Revenue Share by Application (2013-2018)

    9 Middle East and Africa Biosimilar Monoclonal Antibodies by Countries, Type, Application and Manufacturers

    • 9.1 Middle East and Africa Biosimilar Monoclonal Antibodies Sales, Revenue and Market Share by Countries
      • 9.1.1 Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Countries (2013-2018)
      • 9.1.2 Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Countries (2013-2018)
      • 9.1.3 Saudi Arabia Biosimilar Monoclonal Antibodies Sales and Growth Rate (2013-2018)
      • 9.1.4 UAE Biosimilar Monoclonal Antibodies Sales and Growth Rate (2013-2018)
      • 9.1.5 Egypt Biosimilar Monoclonal Antibodies Sales and Growth Rate (2013-2018)
      • 9.1.6 Nigeria Biosimilar Monoclonal Antibodies Sales and Growth Rate (2013-2018)
      • 9.1.7 South Africa Biosimilar Monoclonal Antibodies Sales and Growth Rate (2013-2018)
    • 9.2 Middle East and Africa Biosimilar Monoclonal Antibodies Sales and Revenue (Value) by Manufacturers (2016-2017)
      • 9.2.1 Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Manufacturers (2016-2017)
      • 9.2.2 Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Manufacturers (2016-2017)
    • 9.3 Middle East and Africa Biosimilar Monoclonal Antibodies Sales, Revenue and Market Share by Type (2013-2018)
      • 9.3.1 Middle East and Africa Biosimilar Monoclonal Antibodies Sales and Sales Share by Type (2013-2018)
      • 9.3.1 Middle East and Africa Biosimilar Monoclonal Antibodies Revenue and Revenue Share by Type (2013-2018)
    • 9.4 Middle East and Africa Biosimilar Monoclonal Antibodies Sales, Revenue and Market Share by Application (2013-2018)
      • 9.4.1 Middle East and Africa Biosimilar Monoclonal Antibodies Sales and Sales Share by Application (2013-2018)
      • 9.4.2 Middle East and Africa Biosimilar Monoclonal Antibodies Revenue and Revenue Share by Application (2013-2018)

    10 Global Biosimilar Monoclonal Antibodies Market Segment by Type

    • 10.1 Global Biosimilar Monoclonal Antibodies Sales, Revenue and Market Share by Type (2013-2018)
      • 10.1.1 Global Biosimilar Monoclonal Antibodies Sales and Market Share by Type (2013-2018)
      • 10.1.2 Global Biosimilar Monoclonal Antibodies Revenue and Market Share by Type (2013-2018)
    • 10.2 Rituximab Sales Growth and Price
      • 10.2.1 Global Rituximab Sales Growth (2013-2018)
      • 10.2.2 Global Rituximab Price (2013-2018)
    • 10.3 Infliximab Sales Growth and Price
      • 10.3.1 Global Infliximab Sales Growth (2013-2018)
      • 10.3.2 Global Infliximab Price (2013-2018)
    • 10.4 Abciximab Sales Growth and Price
      • 10.4.1 Global Abciximab Sales Growth (2013-2018)
      • 10.4.2 Global Abciximab Price (2013-2018)
    • 10.5 Trastuzumab Sales Growth and Price
      • 10.5.1 Global Trastuzumab Sales Growth (2013-2018)
      • 10.5.2 Global Trastuzumab Price (2013-2018)
    • 10.6 Adalimumab Sales Growth and Price
      • 10.6.1 Global Adalimumab Sales Growth (2013-2018)
      • 10.6.2 Global Adalimumab Price (2013-2018)
    • 10.7 Bevacizumab Sales Growth and Price
      • 10.7.1 Global Bevacizumab Sales Growth (2013-2018)
      • 10.7.2 Global Bevacizumab Price (2013-2018)

    11 Global Biosimilar Monoclonal Antibodies Market Segment by Application

    • 11.1 Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2013-2018)
    • 11.2 Oncology Sales Growth (2013-2018)
    • 11.3 Chronic and Autoimmune Diseases Sales Growth (2013-2018)
    • 11.4 Growth Hormone Deficiency Sales Growth (2013-2018)
    • 11.5 Infectious Diseases Sales Growth (2013-2018)
    • 11.6 Others Sales Growth (2013-2018)

    12 Biosimilar Monoclonal Antibodies Market Forecast (2018-2023)

    • 12.1 Global Biosimilar Monoclonal Antibodies Sales, Revenue and Growth Rate (2018-2023)
    • 12.2 Biosimilar Monoclonal Antibodies Market Forecast by Regions (2018-2023)
      • 12.2.1 North America Biosimilar Monoclonal Antibodies Market Forecast (2018-2023)
      • 12.2.2 Europe Biosimilar Monoclonal Antibodies Market Forecast (2018-2023)
      • 12.2.3 Asia-Pacific Biosimilar Monoclonal Antibodies Market Forecast (2018-2023)
      • 12.2.4 South America Biosimilar Monoclonal Antibodies Market Forecast (2018-2023)
      • 12.2.5 Middle East and Africa Biosimilar Monoclonal Antibodies Market Forecast (2018-2023)
    • 12.3 Biosimilar Monoclonal Antibodies Market Forecast by Type (2018-2023)
      • 12.3.1 Global Biosimilar Monoclonal Antibodies Sales Forecast by Type (2018-2023)
      • 12.3.2 Global Biosimilar Monoclonal Antibodies Market Share Forecast by Type (2018-2023)
    • 12.4 Biosimilar Monoclonal Antibodies Market Forecast by Application (2018-2023)
      • 12.4.1 Global Biosimilar Monoclonal Antibodies Sales Forecast by Application (2018-2023)
      • 12.4.2 Global Biosimilar Monoclonal Antibodies Market Share Forecast by Application (2018-2023)

    13 Sales Channel, Distributors, Traders and Dealers

    • 13.1 Sales Channel
      • 13.1.1 Direct Marketing
      • 13.1.2 Indirect Marketing
      • 13.1.3 Marketing Channel Future Trend
    • 13.2 Distributors, Traders and Dealers

    14 Research Findings and Conclusion

      15 Appendix

      • 15.1 Methodology

      Summary:
      Get latest Market Research Reports on Biosimilar Monoclonal Antibodies . Industry analysis & Market Report on Biosimilar Monoclonal Antibodies is a syndicated market report, published as Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Biosimilar Monoclonal Antibodies Market 2018, Forecast to 2023. It is complete Research Study and Industry Analysis of Biosimilar Monoclonal Antibodies market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      		$4,880.00
      		$7,320.00
      		$9,760.00
      		3,904.00
      		5,856.00
      		7,808.00
      		4,557.92
      		6,836.88
      		9,115.84
      		770,747.20
      		1,156,120.80
      		1,541,494.40
      		407,138.40
      		610,707.60
      		814,276.80
      Credit card Logo
      Sample Question Discount Download PDF

      Related Reports

      Reason to Buy

      • Trusted By Leaders

        Top executives from leading companies purchase research reports from us. 

      • Shop With Confidence

        We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

      • Customer Centric

        Need assistance related to your research requirements? We are just a phone call or an email away.

      • Personalized Solutions

        Our experienced research specialists are here to help you locate the right reports for your need.

      • Secure Checkout

        Shop without being worried about safety & security of your transactions.
        •

      Request for Sample of this report

      Reports and Markets

      mcafree

      Contact Us

      +1-352-353-0818 (US)

      info@reportsandmarkets.com

      Support

      EMAIL US

      Newsletter

      KEEP UP TO DATE ON ALL THE LATEST REPORTS


      maxmind_logo